These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 36910255)

  • 1. MDM2-BCL-X
    Chang M; Gao F; Chen J; Gnawali G; Wang W
    Acta Mater Med; 2022 Jul; 1(3):333-342. PubMed ID: 36910255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of IAP-recruiting BCL-X
    Zhang X; He Y; Zhang P; Budamagunta V; Lv D; Thummuri D; Yang Y; Pei J; Yuan Y; Zhou D; Zheng G
    Eur J Med Chem; 2020 Aug; 199():112397. PubMed ID: 32388279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of PROTAC BCL-X
    Zhang X; Thummuri D; Liu X; Hu W; Zhang P; Khan S; Yuan Y; Zhou D; Zheng G
    Eur J Med Chem; 2020 Apr; 192():112186. PubMed ID: 32145645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies to Reduce the On-Target Platelet Toxicity of Bcl-x
    Negi A; Voisin-Chiret AS
    Chembiochem; 2022 Jun; 23(12):e202100689. PubMed ID: 35263486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MDM2-Recruiting PROTAC Offers Superior, Synergistic Antiproliferative Activity via Simultaneous Degradation of BRD4 and Stabilization of p53.
    Hines J; Lartigue S; Dong H; Qian Y; Crews CM
    Cancer Res; 2019 Jan; 79(1):251-262. PubMed ID: 30385614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel mechanism of irinotecan targeting MDM2 and Bcl-xL.
    Lee B; Min JA; Nashed A; Lee SO; Yoo JC; Chi SW; Yi GS
    Biochem Biophys Res Commun; 2019 Jun; 514(2):518-523. PubMed ID: 31056264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity.
    Lv D; Pal P; Liu X; Jia Y; Thummuri D; Zhang P; Hu W; Pei J; Zhang Q; Zhou S; Khan S; Zhang X; Hua N; Yang Q; Arango S; Zhang W; Nayak D; Olsen SK; Weintraub ST; Hromas R; Konopleva M; Yuan Y; Zheng G; Zhou D
    Nat Commun; 2021 Nov; 12(1):6896. PubMed ID: 34824248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PROTACs are effective in addressing the platelet toxicity associated with BCL-X
    Zhang P; Zhang X; Liu X; Khan S; Zhou D; Zheng G
    Explor Target Antitumor Ther; 2020; 1(4):259-272. PubMed ID: 34296214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The PROTAC selectively degrading Bcl-x
    Zhang S; Chen Y; Xu Z; Yang J; Sun R; Wang J; Sun Y; Jiang B; Yang X; Tan W
    Theranostics; 2022; 12(17):7476-7490. PubMed ID: 36438482
    [No Abstract]   [Full Text] [Related]  

  • 10. Structural Insights into PROTAC-Mediated Degradation of Bcl-xL.
    Chung CW; Dai H; Fernandez E; Tinworth CP; Churcher I; Cryan J; Denyer J; Harling JD; Konopacka A; Queisser MA; Tame CJ; Watt G; Jiang F; Qian D; Benowitz AB
    ACS Chem Biol; 2020 Sep; 15(9):2316-2323. PubMed ID: 32697072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of a Novel BCL-X
    Pal P; Thummuri D; Lv D; Liu X; Zhang P; Hu W; Poddar SK; Hua N; Khan S; Yuan Y; Zhang X; Zhou D; Zheng G
    J Med Chem; 2021 Oct; 64(19):14230-14246. PubMed ID: 34533954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PROTAC Degraders with Ligands Recruiting MDM2 E3 Ubiquitin Ligase: An Updated Perspective.
    Han X; Wei W; Sun Y
    Acta Mater Med; 2022; 1(2):244-259. PubMed ID: 35734447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Homo-PROTAC mediated suicide of MDM2 to treat non-small cell lung cancer.
    He S; Ma J; Fang Y; Liu Y; Wu S; Dong G; Wang W; Sheng C
    Acta Pharm Sin B; 2021 Jun; 11(6):1617-1628. PubMed ID: 34221872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PROTAC-mediated dual degradation of BCL-xL and BCL-2 is a highly effective therapeutic strategy in small-cell lung cancer.
    Khan S; Cao L; Wiegand J; Zhang P; Zajac-Kaye M; Kaye FJ; Zheng G; Zhou D
    bioRxiv; 2024 Mar; ():. PubMed ID: 38464204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. E3 Ligase Ligands in Successful PROTACs: An Overview of Syntheses and Linker Attachment Points.
    Bricelj A; Steinebach C; Kuchta R; Gütschow M; Sosič I
    Front Chem; 2021; 9():707317. PubMed ID: 34291038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MDM2-Based Proteolysis-Targeting Chimeras (PROTACs): An Innovative Drug Strategy for Cancer Treatment.
    Vicente ATS; Salvador JAR
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of E3 Ligase Ligands for Target Protein Degradation.
    Lee J; Lee Y; Jung YM; Park JH; Yoo HS; Park J
    Molecules; 2022 Oct; 27(19):. PubMed ID: 36235052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future.
    Li R; Liu M; Yang Z; Li J; Gao Y; Tan R
    Molecules; 2022 Dec; 27(24):. PubMed ID: 36557960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and crystal structures of a potent second-generation dual degrader of BCL-2 and BCL-xL.
    Nayak D; Lv D; Yuan Y; Zhang P; Hu W; Nayak A; Ruben EA; Lv Z; Sung P; Hromas R; Zheng G; Zhou D; Olsen SK
    Nat Commun; 2024 Mar; 15(1):2743. PubMed ID: 38548768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells.
    Carter BZ; Mak PY; Mak DH; Ruvolo VR; Schober W; McQueen T; Cortes J; Kantarjian HM; Champlin RE; Konopleva M; Andreeff M
    Oncotarget; 2015 Oct; 6(31):30487-99. PubMed ID: 26431162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.